Daniel P Rossignol

Summary

Affiliation: Eisai Medical Research
Country: USA

Publications

  1. ncbi Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist
    Maureen Mullarkey
    Biology Section, Eisai Research Institute of Boston, Inc, Andover, Massachusetts, USA
    J Pharmacol Exp Ther 304:1093-102. 2003
  2. doi Continuous pharmacodynamic activity of eritoran tetrasodium, a TLR4 antagonist, during intermittent intravenous infusion into normal volunteers
    Daniel P Rossignol
    Eisai Medical Research Inc, Ridgefield Park, New Jersey 07660, USA
    Innate Immun 14:383-94. 2008
  3. ncbi Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogue
    Daniel P Rossignol
    Eisai Medical Research Inc, Teaneck, New Jersey 07666, USA
    J Endotoxin Res 8:483-8. 2002
  4. ncbi TLR4 antagonists for endotoxemia and beyond
    Daniel P Rossignol
    Eisai Medical Research Inc, NJ 07660, USA
    Curr Opin Investig Drugs 6:496-502. 2005
  5. pmc Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of eritoran (E5564) during continuous intravenous infusion into healthy volunteers
    Daniel P Rossignol
    Eisai Medical Research, Inc, Glenpointe Centre West, 500 Frank W Burr Blvd, Teaneck, NJ 07666 6741, USA
    Antimicrob Agents Chemother 48:3233-40. 2004
  6. ncbi Extended in vivo pharmacodynamic activity of E5564 in normal volunteers with experimental endotoxemia [corrected]
    Melvyn Lynn
    Eisai Medical Research Inc, Glenpointe Centre West, Teaneck, New Jersey 07666 6741, USA
    J Pharmacol Exp Ther 308:175-81. 2004
  7. ncbi Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia
    Melvyn Lynn
    Eisai Medical Research, Teaneck, New Jersey 07666 6741, USA
    J Infect Dis 187:631-9. 2003
  8. ncbi Inhibition of endotoxin response by synthetic TLR4 antagonists
    Lynn D Hawkins
    Eisai Medical Research Inc, Andover, MA, USA
    Curr Top Med Chem 4:1147-71. 2004
  9. pmc Association of the endotoxin antagonist E5564 with high-density lipoproteins in vitro: dependence on low-density and triglyceride-rich lipoprotein concentrations
    Kishor M Wasan
    Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada
    Antimicrob Agents Chemother 47:2796-803. 2003
  10. ncbi Influence of plasma cholesterol and triglyceride concentrations and eritoran (E5564) micelle size on its plasma pharmacokinetics and ex vivo activity following single intravenous bolus dose into healthy female rabbits
    Kishor M Wasan
    Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada
    Pharm Res 25:176-82. 2008

Collaborators

Detail Information

Publications12

  1. ncbi Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist
    Maureen Mullarkey
    Biology Section, Eisai Research Institute of Boston, Inc, Andover, Massachusetts, USA
    J Pharmacol Exp Ther 304:1093-102. 2003
    ..These results indicate that E5564 is a potent antagonist of LPS and lacks agonistic activity in human and animal model systems, making it a potentially effective therapeutic agent for treatment of disease states caused by endotoxin...
  2. doi Continuous pharmacodynamic activity of eritoran tetrasodium, a TLR4 antagonist, during intermittent intravenous infusion into normal volunteers
    Daniel P Rossignol
    Eisai Medical Research Inc, Ridgefield Park, New Jersey 07660, USA
    Innate Immun 14:383-94. 2008
    ..The objective of this study was to assess the safety, and pharmacokinetic and pharmacodynamic profile of E5564 infused twice-daily at three target steady-state plasma levels of approximately 1, 3 and 10 microg/ml in healthy volunteers...
  3. ncbi Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogue
    Daniel P Rossignol
    Eisai Medical Research Inc, Teaneck, New Jersey 07666, USA
    J Endotoxin Res 8:483-8. 2002
    ..Results from these multiple-dose studies indicate that under these conditions of administration, plasma levels of E5564 can be predictive of long-term pharmacodynamic activity...
  4. ncbi TLR4 antagonists for endotoxemia and beyond
    Daniel P Rossignol
    Eisai Medical Research Inc, NJ 07660, USA
    Curr Opin Investig Drugs 6:496-502. 2005
    ..This review discusses current, preclinical and clinical research regarding eritoran (E-5564), an analog of the non-toxic lipid A from Rhodobacter sphaeroides, as well as other antagonists of TLR4 in a variety of diseases...
  5. pmc Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of eritoran (E5564) during continuous intravenous infusion into healthy volunteers
    Daniel P Rossignol
    Eisai Medical Research, Inc, Glenpointe Centre West, 500 Frank W Burr Blvd, Teaneck, NJ 07666 6741, USA
    Antimicrob Agents Chemother 48:3233-40. 2004
    ....
  6. ncbi Extended in vivo pharmacodynamic activity of E5564 in normal volunteers with experimental endotoxemia [corrected]
    Melvyn Lynn
    Eisai Medical Research Inc, Glenpointe Centre West, Teaneck, New Jersey 07666 6741, USA
    J Pharmacol Exp Ther 308:175-81. 2004
    ..No differences were observed. These results demonstrate that E5564 blocks the effects of endotoxin in a human model of clinical sepsis and indicate its potential in the treatment and/or prevention of clinical sepsis...
  7. ncbi Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia
    Melvyn Lynn
    Eisai Medical Research, Teaneck, New Jersey 07666 6741, USA
    J Infect Dis 187:631-9. 2003
    ..01). These results demonstrate that E5564 blocks the effects of LPS in a human model of clinical sepsis and indicate its potential in the treatment and/or prevention of clinical sepsis...
  8. ncbi Inhibition of endotoxin response by synthetic TLR4 antagonists
    Lynn D Hawkins
    Eisai Medical Research Inc, Andover, MA, USA
    Curr Top Med Chem 4:1147-71. 2004
    ..This review discusses the evolution of synthetic LPS antagonists with emphasis on the SAR and development of E5564 and its precursors...
  9. pmc Association of the endotoxin antagonist E5564 with high-density lipoproteins in vitro: dependence on low-density and triglyceride-rich lipoprotein concentrations
    Kishor M Wasan
    Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada
    Antimicrob Agents Chemother 47:2796-803. 2003
    ..Information from these studies could be used to help identify the possible components of lipoproteins which influence the interaction of E5564 with specific lipoprotein particles...
  10. ncbi Influence of plasma cholesterol and triglyceride concentrations and eritoran (E5564) micelle size on its plasma pharmacokinetics and ex vivo activity following single intravenous bolus dose into healthy female rabbits
    Kishor M Wasan
    Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada
    Pharm Res 25:176-82. 2008
    ..This was done with eritoran administered as stable micelle formulations of mean hydrodynamic diameters of 8 or 27 nm)...
  11. ncbi A novel class of endotoxin receptor agonists with simplified structure, toll-like receptor 4-dependent immunostimulatory action, and adjuvant activity
    Lynn D Hawkins
    Department of Medicinal Chemistry, Signal Transduction Research, Eisai Research Institute, Andover, Massachusetts 01810, USA
    J Pharmacol Exp Ther 300:655-61. 2002
    ..Our results indicate that these unique compounds behave as agonists of TLR4, resulting in responses similar to those elicited by LPS. They display adjuvant activity in vivo and may be useful for the development of vaccine therapies...
  12. ncbi A phase II, double-blind, placebo-controlled, ascending-dose study of Eritoran (E5564), a lipid A antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass
    Elliott Bennett-Guerrero
    Department of Anesthesiology, Duke University Medical Center, Durham, NC 27710, USA
    Anesth Analg 104:378-83. 2007
    ..In this study we assessed the safety of eritoran administration in patients undergoing cardiac surgery and obtained preliminary efficacy data for the prophylaxis of endotoxin-mediated surgical complications...